口服阿扎胞苷调节急性髓系白血病缓解期患者的骨髓微环境:QUAZAR AML-001 试验的子分析
QUAZAR AML-001 三期试验的子分析对强化化疗后缓解的 AML 患者骨髓进行免疫分析,发现缓解后淋巴细胞、单核细胞、T 细胞及 CD34+CD117+ 骨髓细胞水平升高对无复发生存有利,口服阿扎胞苷维持治疗可增加早期 T 细胞数量、提高 CD4+:CD8+ 比值并逆转 T 细胞耗竭,这些免疫介导反应与临床结局相关。
要点
- 强化化疗后缓解时淋巴细胞、单核细胞、T 细胞及 CD34+CD117+ 骨髓细胞水平升高与无复发生存有利相关。
- CD3+ T 细胞计数在两个治疗组中均对无复发生存有显著预后意义。
- 口服阿扎胞苷维持治疗可增加早期 T 细胞数量、提高 CD4+:CD8+ 比值并逆转 T 细胞耗竭。
核心结论
- 口服阿扎胞苷在 AML 维持治疗中调节 T 细胞活性,这些免疫介导的反应与临床结局相关。
研究设计与样本
- QUAZAR AML-001 三期试验的子分析,对强化化疗后缓解的 AML 患者骨髓在缓解时和治疗中进行免疫分析。
主要发现
- 强化化疗后淋巴细胞、单核细胞、T 细胞及 CD34+CD117+ 骨髓细胞水平升高对无复发生存有利。
- CD3+ T 细胞计数在两个治疗组中均对无复发生存有显著预后意义。
- 基线时部分 CD34+CD117+ 骨髓细胞高表达 PD-L1,其中许多为 PD-L2+;T 细胞耗竭标志物 PD-1 和 TIM-3 高共表达与较差结局相关。
- 口服阿扎胞苷在早期治疗中增加 T 细胞数量、提高 CD4+:CD8+ 比值并逆转 T 细胞耗竭。
- 无监督聚类分析识别出两个由 T 细胞含量和 T 细胞耗竭标志物表达定义的患者亚群,这些亚群富含微小残留病阴性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oral azacitidine (Oral-AZA) maintenance therapy improved relapse-free (RFS) and overall survival (OS) significantly versus placebo for AML patients in remission after intensive chemotherapy (IC) in the phase 3 QUAZAR AML-001 study. Immune profiling was performed on the bone marrow (BM) at remission and on-treatment in a subset of patients with the aim of identifying prognostic immune features and evaluating associations of on-treatment immune effects by Oral-AZA with clinical outcomes. Post-IC, increased levels of lymphocytes, monocytes, T cells and CD34 + CD117+ BM cells were prognostically favourable for RFS. CD3+ T-cell counts were significantly prognostic for RFS in both treatment arms. At baseline, high expression of the PD-L1 checkpoint marker was identified on a subset of CD34 + CD117+ BM cells; many of which were PD-L2+. High co-expression of T-cell exhaustion markers PD-1 and TIM-3 was associated with inferior outcomes. Oral-AZA augmented T-cell numbers during early treatment, increased CD4+:CD8+ ratios and reversed T-cell exhaustion. Unsupervised clustering analysis identified two patient subsets defined by T-cell content and expression of T-cell exhaustion markers that were enriched for MRD negativity. These results indicate that Oral-AZA modulates T-cell activity in the maintenance setting of AML, and these immune-mediated responses are associated with clinical outcomes.
引用
- Menezes DL, See WL, Risueño A, et al. Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial. Br J Haematol. 2023. PMID: 36990798. doi:10.1111/bjh.18783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。